Since targeted agents are currently being tested in clinical trials, determining the HER2 status can influence the treatment of patients with molecularly defined lung adenocarcinoma, as well as provide prognostic stratification.6.7 This evidence concerns the gene ERBB2 and lung adenocarcinoma.